Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Novo Nordisk A/S
Study ID
NCT05725902
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

  • Etavopivat — DRUG
    The study intervention is etavopivat (400 mg), administered orally and once daily (QD)

Study Details

An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.

Key Dates

Start date
Mar 9, 2024
Status verified
Apr 2026
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Etavopivat
    Single-arm, open-label

Primary Outcome Measure

Effect of etavopivat on cerebral blood flow (CBF) [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Emory University Children's Healthcare of AtlantaAtlantaGeorgia30342-

Find similar trials in Atlanta, GA

By condition
Sickle cell disease
By research site
Emory University Children's Healthcare of Atlanta· Atlanta, GA

Related Studies